Sector
PharmaceuticalsOpen
₹465.95Prev. Close
₹466.6Turnover(Lac.)
₹126.2Day's High
₹478.95Day's Low
₹45652 Week's High
₹53052 Week's Low
₹152.22Book Value
₹27.72Face Value
₹1Mkt Cap (₹ Cr.)
3,436.4P/E
57.32EPS
8.14Divi. Yield
0.2113 May 2023
12:00 AM
Split
13 May 2023
12:00 AM
AGM
Announcement Date: 13 May, 2023
14 May 2024
12:00 AM
Dividend
Dividend Amount: 0.25
14 May 2024
12:00 AM
BookCloser
3 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 7.26 | 7.26 | 7.26 | 7.26 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 194.11 | 141.88 | 96.06 | 62.68 |
Net Worth | 201.37 | 149.14 | 103.32 | 69.94 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 90.56 | 85.12 | 38.79 | 35.69 |
yoy growth (%) | 6.38 | 119.39 | 8.7 | 9.4 |
Raw materials | -15.37 | -11.33 | -2.15 | -1.48 |
As % of sales | 16.97 | 13.31 | 5.55 | 4.16 |
Employee costs | -7.11 | -6.43 | -4.45 | -4.41 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 40.88 | 31.25 | 4.83 | 4.88 |
Depreciation | -1.73 | -1.36 | -1.14 | -1.11 |
Tax paid | -10.7 | -7.58 | -0.97 | -0.5 |
Working capital | 34.58 | 16.25 | 0.88 | 3.46 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.38 | 119.39 | 8.7 | 9.4 |
Op profit growth | 26.67 | 410.27 | 3.15 | -0.1 |
EBIT growth | 30.09 | 512.27 | -0.7 | 5.32 |
Net profit growth | 27.47 | 512.18 | -11.65 | -5.44 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Dinesh S Patel
Non Executive Director
Sachin D Patel
Independent Non Exe. Director
VIJAY GOPI KISHAN AGARWAL
Independent Non Exe. Director
Kirandeep Madan
Independent Non Exe. Director
Vikram D Sanghvi
Independent Non Exe. Director
Siddharth Y Kusumgar
Company Sec. & Compli. Officer
RAHUL DWARAKA SONI
Independent Director
Hitesh Dharmasinh Gajaria
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gujarat Themis Biosyn Ltd
Summary
Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL.During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the
Read More
What is the Gujarat Themis Biosyn Ltd share price today?
The Gujarat Themis Biosyn Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹473.05 today.
What is the Market Cap of Gujarat Themis Biosyn Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd is ₹3436.40 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Gujarat Themis Biosyn Ltd?
The PE and PB ratios of Gujarat Themis Biosyn Ltd is 57.32 and 16.83 as of 22 Jul ‘24
What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?
The 52-week high/low is the highest and lowest price at which a Gujarat Themis Biosyn Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gujarat Themis Biosyn Ltd is ₹152.22 and ₹530 as of 22 Jul ‘24
What is the CAGR of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd's CAGR for 5 Years at 128.08%, 3 Years at 71.69%, 1 Year at 197.35%, 6 Month at 48.62%, 3 Month at 20.94% and 1 Month at -6.81%.
What is the shareholding pattern of Gujarat Themis Biosyn Ltd?
The shareholding pattern of Gujarat Themis Biosyn Ltd is as follows:
Promoters - 70.86 %
Institutions - 2.62 %
Public - 26.52 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
